BICYCLE THERAPEUTICS PLC

For the period ended Sep 30, 2025. Filed Oct 30, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Oct 30, 2025

BCYC$3.69-2.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share data)


· · Three Months Ended · · Nine Months Ended
· · September 30, · · September 30,
· 2025 · 2024 · 2025 · 2024
Collaboration revenue	$11,734	$2,676	$24,631	$31,567
Operating expenses:
Research and development	58,426	48,265	188,513	123,188
General and administrative	18,859	18,257	58,475	50,588
Total operating expenses	77,285	66,522	246,988	173,776
Loss from operations	(65,551)	(63,846)	(222,357)	(142,209)
Other income (expense):
Interest and other income	6,700	10,583	22,587	23,981
Interest expense	(44)	(33)	(149)	(1,678)
Loss on extinguishment of debt	—	(954)	—	(954)
Total other income, net	6,656	9,596	22,438	21,349
Net loss before income tax provision	(58,895)	(54,250)	(199,919)	(120,860)
Provision for (benefit from) income taxes	205	(3,448)	(1,113)	(3,683)
Net loss	$(59,100)	$(50,802)	$(198,806)	$(117,177)
Net loss per share, basic and diluted	$(0.85)	$(0.74)	$(2.87)	$(2.15)
Weighted average ordinary shares outstanding, basic and diluted	69,303,746	68,988,858	69,251,291	54,566,490

Comprehensive loss:
Net loss	$(59,100)	$(50,802)	$(198,806)	$(117,177)
Other comprehensive income (loss):
Foreign currency translation adjustment	(108)	(2,093)	(3,590)	(1,881)
Total comprehensive loss	$(59,208)	$(52,895)	$(202,396)	$(119,058)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.